Home » Archives for Harald » Page 39

Author Archives: Harald

Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 1)

Posted on by — No Comments ↓

When Roche inlicensed Polyphor’s anti-pseudomonas drug POL7080 in November 2013, it marked a turning point. It seemed that Big Pharma that had all but abandoned the field in the last decade and was getting engaged in anti-infectives again. When a company with as much experience in antibiotic drug development as Roche Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 1)→

Two New Antifungals Presented at ICAAC San Diego

Posted on by — No Comments ↓

As noticed by many other colleagues, ICAAC 2015 was a shadow of its former self.  Few participants overall, fewer posters, and even fewer exhibitors.  Reviewing the posters, there were relatively few from industry, most came from university or small research labs.  In a way, ICAAC 2015 was a true reflection of Continue reading Two New Antifungals Presented at ICAAC San Diego→

After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2

Posted on by — 1 Comment ↓

When a well-designed pivotal Phase 3 trial fails to show NI, it demands an explanation.  While awaiting the company’s analysis of the data, many possible explanations are bandied about.  So it was not surprising that the eravacycline cUTI study (IGNITE-2) was mentioned quite often during ICAAC 2015, in sessions and Continue reading After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2→